Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.

NCT02159066 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02159066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02159066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
July 23, 2014
Completion date
January 10, 2023
Enrollment
158 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma